Search
-
ESG in life sciences as a hidden driver for brand success
There is a growing belief among the public that private corporations should also take responsibility for environmental, social, and governance (ESG) issues; these factors are no longer solely the responsibility of the public and governments. While certain business sectors are perceived as having a heightened obligation to diminish their environmental footprint (particularly energy companies, automobile manufacturers, airlines, and public transport providers), no industry can evade the necessity to act responsibly.
-
The Future of Point of Care & Rapid Testing
How have the Point of Care (PoC) and rapid testing markets evolved over the past two years? What are the key challenges, unmet needs and opportunities for companies working in POC & rapid testing today?
-
The Future of point of care (PoC) & rapid testing [webinar recording]
How has the Point of Care (PoC) and rapid testing market evolved, and what does the future hold? What are the key challenges, unmet needs and opportunities for companies working in PoC & rapid testing today?
-
[EVENT] BIO International Convention
On June 3, Ipsos is delighted to be exhibiting at BIO International, the global gathering of biotechnology and pharmaceutical leaders.
-
The Path to Patient Centricity: Closing the 'How' Gap
Today, patient centricity is not only well documented in corporate visions and missions, it’s at the top of many pharmaceutical company agendas. Clearly, there is both a need for it and an appetite for it among those best placed to make it happen. The question that remains for pharma and biotechs is how best to be patient-centric…
-
[EVENT] Wired Health - Innovation for Life
March 15 - Wired Health is the Wired Italia event dedicated to health technologies.
-
Who Will Win the Race to Treat NASH?
Non-alcoholic Steatohepatitis, or NASH, is a liver disease characterized by rising prevalence, low diagnosis and a lack of therapies approved for treatment. All of these factors combine to make NASH a priority for the healthcare industry – and, potentially, a multi-billion-dollar market. Accordingly, the race is now on among several pharma companies to develop the first effective pharmacotherapy to treat NASH.